

# ACT Onco<sup>®</sup> + Report

PATIENT		
Identifier: 傅瑞瑄		Patient ID: 49324563
Date of Birth: Jan 17, 1972		Gender: Female
Diagnosis: Lung adenocarcinoma		
ORDERING PHYSICIAN		
Name: 沈佳儀醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11211680A	Collection site: Lung	Type: FFPE tissue
Date received: Jun 30, 2023	Lab ID: AA-23-04287	D/ID: NA

## ABOUT ACTOnco<sup>®</sup>+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) ( $\leq 15$  nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

## SUMMARY FOR ACTIONABLE VARIANTS

### VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
EGFR L858R	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib	-	-

### VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
	Not detected	

#### Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

# ACTOnco® + Report

## TESTING RESULTS

### VARIANT(S) WITH CLINICAL RELEVANCE

#### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
<i>EGFR</i>	L858R	28.0%
<i>TP53</i>	T155N	25.7%

#### - Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr13	<i>BRCA2</i>	Heterozygous deletion	1
Chr17	<i>NF1</i>	Heterozygous deletion	1

#### - Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

#### - Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	0.1 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

#### Note:

- Variant(s) enlisted in the SNV table may currently exhibit no relevance to treatment response prediction. Please refer to INTERPRETATION for more biological information and/or potential clinical impacts of the variants.
- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 40% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco®+ to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at  $\geq 7.5$  mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is  $< 30\%$ .

# ACT Onco<sup>®</sup> + Report

## THERAPEUTIC IMPLICATIONS

### TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
<b>Level 1</b>		
<b>EGFR</b> L858R	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib	<b>sensitive</b>

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
<b>1</b>	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
<b>2</b>	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
<b>3A</b>	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
<b>3B</b>	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
<b>4</b>	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

# ACT Onco<sup>®</sup> + Report

## IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

### - Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
EGFR aberration	Likely associated with WORSE response to ICIs

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

## CHEMOTHERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to chemotherapies.

## HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

## OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

### Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

# ACT Onco<sup>®</sup> + Report

## VARIANT INTERPRETATION

### EGFR L858R

#### Biological Impact

The EGFR gene encodes for the Epidermal Growth Factor Receptor, a receptor tyrosine kinase which binds to its ligands, including Epidermal Growth Factor (EGF) and Transforming Growth Factor- $\alpha$  (TGF- $\alpha$ ), activates downstream signaling pathways, including the canonical oncogenic MAPK and PI3K/AKT/m TOR signaling cascades<sup>[1]</sup>. Increased EGFR activity by mutations and/or amplification of the EGFR gene has been described in a wide range of cancers, such as lung, brain, colorectal and head and neck cancer<sup>[2]</sup>. Mutations in the kinase domain of EGFR are commonly observed in non-small cell lung cancer (NSCLC), resulting in a constitutively activated form of the receptor<sup>[3]</sup>. On the other hand, in the brain and colorectal cancers, the most prevalent EGFR alteration is copy number amplification that results in receptor overexpression<sup>[4]</sup>.

EGFR L858R is a missense mutation at position 858, located in exon 21, which encodes part of the kinase domain, from a leucine to an arginine residue<sup>[5]</sup>. The two most common EGFR alterations, L858R mutation and exon 19 deletions can result in constitutive activation of signal transduction pathways, leading to cell proliferation or anti-apoptosis without ligand binding<sup>[6]</sup>.

#### Therapeutic and prognostic relevance

There is accumulated clinical evidence suggested that patients with MDM2/MDM4 amplification or EGFR aberrations exhibited poor clinical outcome and demonstrated a significantly increased rate of tumor growth (hyper-progression) after receiving immune checkpoint (PD-1/PD-L1) inhibitors therapies<sup>[7]</sup> (Annals of Oncology (2017) 28 (suppl\_5): v403-v427. 10.1093/annonc/mdx376).

EGFR mutation has been determined as an inclusion criteria for the trials examining afatinib efficacy in malignant glioma and pediatric tumors (NCT02423525, NCT02372006). The first- and second-generation EGFR-TKIs, including dacomitinib, erlotinib, gefitinib, and afatinib, have been approved by the U.S. FDA as first-line treatments for non-small cell lung cancer patients with EGFR exon 19 deletion or L858R mutation. Osimertinib, a third-generation EGFR-TKI, has also been approved by the U.S. FDA. It is indicated for adjuvant treatment or first-line treatment of metastatic NSCLC patients with EGFR exon 19 deletion or L858R mutation.

A phase III trial (NCT01774721) show that dacomitinib significantly improved PFS over gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC<sup>[8]</sup>. Another phase III trial (NCT00949650) demonstrated that median PFS among lung cancer patients with exon 19 deletion or L858R EGFR mutation (n=308) was 13.6 months for afatinib and 6.9 months for chemotherapy<sup>[9]</sup>. Results from a double-blind, phase 3 trial further showed that osimertinib significantly demonstrated longer PFS than standard EGFR-TKIs (18.9 months vs. 10.2 months) in previously untreated EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC<sup>[10]</sup>.

### TP53 T155N

#### Biological Impact

TP53 encodes the p53 protein, a crucial tumor suppressor that orchestrates essential cellular processes including cell cycle arrest, senescence and apoptosis<sup>[11]</sup>. TP53 is a proto-typical haploinsufficient gene, such that loss of a single copy of TP53 can result in tumor formation<sup>[12]</sup>.

#### Therapeutic and prognostic relevance

Despite having a high mutation rate in cancers, there are currently no approved targeted therapies for TP53 mutations. A phase II trial demonstrated that Wee1 inhibitor (AZD1775) in combination with carboplatin was well tolerated and showed promising anti-tumor activity in TP53-mutated ovarian cancer refractory or resistant (< 3 months) to standard first-line therapy (NCT01164995)<sup>[13]</sup>.

# ACT Onco<sup>®</sup> + Report

In a retrospective study (n=19), advanced sarcoma patients with TP53 loss-of-function mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with pazopanib<sup>[14]</sup>. Results from another Phase I trial of advanced solid tumors (n=78) demonstrated that TP53 hotspot mutations are associated with better clinical response to the combination of pazopanib and vorinostat<sup>[15]</sup>.

Advanced solid tumor and colorectal cancer patients harboring a TP53 mutation have been shown to be more sensitive to bevacizumab when compared with patients harboring wild-type TP53<sup>[16][17][18]</sup>. In a pilot trial (n=21), TP53-negative breast cancer patients demonstrated increased survival following treatment with bevacizumab in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel)<sup>[19]</sup>. TP53 mutations were correlated with poor survival of advanced breast cancer patients receiving tamoxifen or primary chemotherapy<sup>[20][21]</sup>. In a retrospective study of non-small cell lung cancer (NSCLC), TP53 mutations were associated with high expression of VEGF-A, the primary target of bevacizumab, offering a mechanistic explanation for why patients exhibit improved outcomes after bevacizumab treatment when their tumors harbor mutant TP53 versus wild-type TP53<sup>[22]</sup>.

## **BRCA2 Heterozygous deletion**

### **Biological Impact**

The BRCA2 gene encodes a tumor suppressor involved in the homologous recombination pathway for double-strand DNA repair<sup>[23]</sup>. BRCA2 has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions<sup>[24]</sup>. BRCA2 germline mutations confer an increased lifetime risk of developing breast, ovarian, prostate and pancreatic cancer, limited reports of related gastric cancer, and Fanconi anemia subtype D1-associated risk of brain cancer, medulloblastoma, pharyngeal cancer, chronic lymphocytic leukemia and acute myeloid leukemia<sup>[25]</sup>. Somatic mutations in BRCA2 are highest in colorectal, non-small cell lung cancer (NSCLC), and ovarian cancers<sup>[26]</sup>.

### **Therapeutic and prognostic relevance**

Multiple PARP inhibitors, including olaparib, rucaparib, niraparib, and talazoparib, have been approved by the U.S. FDA for the treatment of cancer. Olaparib is approved for multiple settings in advanced ovarian cancer, metastatic breast cancer with BRCA mutations, metastatic pancreatic cancer, and mCRPC with BRCA mutation or HRR gene mutations, including BRCA. Rucaparib is approved for maintenance treatment of recurrent ovarian cancer with BRCA mutations and mCRPC with BRCA mutations. Niraparib is approved for maintenance treatment of advanced ovarian cancer and recurrent ovarian cancer with BRCA mutations. Talazoparib is approved for locally advanced or metastatic breast cancer with BRCA mutations and mCRPC with HRR gene mutations, including BRCA.

According to the NCCN guidelines, rucaparib is recommended as recurrence therapy for patients with BRCA-mutated ovarian cancer who have been treated with multiple lines of chemotherapy. It is also recommended as maintenance therapy for patients with metastatic pancreatic cancer who have undergone prior platinum-based therapy and harbor germline or somatic BRCA mutations. Additionally, niraparib is recommended as maintenance therapy for ovarian cancer patients with BRCA mutations.

## **NF1 Heterozygous deletion**

### **Biological Impact**

The neurofibromin 1 (NF1) gene encodes a GTPase activating protein (GAP) which is an important negative regulator of the Ras cellular proliferation pathways<sup>[27][28][29][30]</sup>. Besides, NF1 also physically interacts with the N-terminal domain of focal adhesion kinase (FAK) and involves in the regulation of cell adhesion, growth, and other pathways<sup>[31][32]</sup>. NF1 is considered a classical haploinsufficient tumor suppressor gene with loss of one allele through inherited or acquired mutation may lead to reduced protein expression and is insufficient to execute normal cellular functions contributing to tumor development<sup>[33][34][35][36][37]</sup>. NF1 syndrome is a germline condition resulting in a predisposition to several types of



# ACT Onco<sup>®</sup> + Report

cancer such as neurofibromas, melanoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, hematological malignancies<sup>[38][39][40]</sup>. Meanwhile, sporadic NF1 mutations have been observed in multiple cancer types<sup>[41]</sup>, including myelodysplastic syndromes, melanomas, colon cancer<sup>[42]</sup>, glioblastomas<sup>[43]</sup>, lung cancer<sup>[44]</sup>, ovarian cancer, and breast cancer<sup>[38]</sup>.

## Therapeutic and prognostic relevance

Selumetinib is FDA-approved for treating pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

In the NCCN guidelines for CNS cancers, selumetinib is recommended as a treatment option for recurrent or progressive NF-1 mutated glioma patient.

NF1 mutation/loss has been determined as an inclusion criterion for the trials evaluating selumetinib efficacy in solid tumors (NCT02664935, NCT03155620)<sup>[45]</sup>.

NF1 depletion is associated with drug resistance to various inhibitors, such as RAF, EGFR, tamoxifen, and retinoic acid<sup>[41][46]</sup>. Loss of NF1 in lung adenocarcinomas, colorectal cancer, and BRAF-mutated melanomas is associated with resistance to anti-EGFR and BRAF inhibitors<sup>[47][48][49][50][51][52]</sup>. NF1 loss contributes to trastuzumab resistance in HER2-positive metastatic gastric cancer, but a combination of HER2 and MEK/ERK inhibitors may overcome this resistance<sup>[53]</sup>. Trametinib is effective in treating neurofibromatosis type I-associated glioblastoma<sup>[54]</sup>. Patients with mutations in the mTOR pathway, including NF1, have responded to everolimus<sup>[55]</sup>. However, a patient with metastatic lung cancer harboring CCDC6-ROS1 and NF1 truncating mutation treated with crizotinib had a short overall survival of one month<sup>[56]</sup>.

NF1 depletion has been linked to drug resistance to several inhibitors in vitro, including RAF, EGFR, and trastuzumab. However, adding MEK inhibitors could restore sensitivity to erlotinib<sup>[47]</sup>, and MEK and mTOR inhibitors showed promise in NF1-deficient tumors<sup>[57][58]</sup>. Knockdown of NF1 also led to resistance to crizotinib and cabozantinib treatment in ROS1 fusion-positive cells<sup>[56]</sup>.

# ACT Onco<sup>®</sup> + Report

## US FDA-APPROVED DRUG(S)

### Afatinib (GILOTRIF)

Afatinib acts as an irreversible covalent inhibitor of the ErbB family of receptor tyrosine kinases, including epidermal growth factor receptor (EGFR) and erbB-2 (HER2). Afatinib is developed and marketed by Boehringer Ingelheim under the trade name GILOTRIF (United States) and GIOTRIF (Europe).

#### - FDA Approval Summary of Afatinib (GILOTRIF)

LUX-Lung 8 <sup>[59]</sup> NCT01523587	Non-small cell lung carcinoma (Approved on 2016/04/15)
	EGFR ex19del or L858R
	Afatinib vs. Erlotinib [PFS(M): 2.4 vs. 1.9]
LUX-Lung 3 <sup>[60]</sup> NCT00949650	Non-small cell lung carcinoma (Approved on 2013/07/13)
	EGFR ex19del or L858R
	Afatinib vs. Pemetrexed + cisplatin [PFS(M): 11.1 vs. 6.9]

### Binimetinib (MEKTOVI)

Binimetinib is an oral kinase inhibitor that targets MEK. Binimetinib is developed and marketed by Array BioPharma under the trade name MEKTOVI.

#### - FDA Approval Summary of Binimetinib (MEKTOVI)

MEKTOVI <sup>[61]</sup> NCT01909453	Melanoma (Approved on 2018/06/27)
	BRAF V600E/K
	Encorafenib + binimetinib vs. Vemurafenib [PFS(M): 14.9 vs. 7.3]

### Cobimetinib (COTELLIC)

Cobimetinib is a reversible inhibitor which targets MEK1 and MEK2. Cobimetinib is developed by Exelixis and Genentech, and marketed by Genentech under the trade name COTELLIC.

#### - FDA Approval Summary of Cobimetinib (COTELLIC)

coBRIM <sup>[62]</sup> NCT01689519	Melanoma (Approved on 2015/11/10)
	BRAF V600E/K
	Cobimetinib + vemurafenib vs. Placebo + vemurafenib [PFS(M): 12.3 vs. 7.2]

### Dacomitinib (VIZIMPRO)

Dacomitinib is an oral kinase inhibitor that targets EGFR. Dacomitinib is developed and marketed by Pfizer under the trade name VIZIMPRO.

#### - FDA Approval Summary of Dacomitinib (VIZIMPRO)

ARCHER 1050 <sup>[8]</sup> NCT01774721	Non-small cell lung carcinoma (Approved on 2018/09/27)
	EGFR ex19del or L858R
	Dacomitinib vs. Gefitinib [PFS(M): 14.7 vs. 9.2]



# ACT Onco® + Report

## Erlotinib (TARCEVA)

Erlotinib is a small molecule, reversible inhibitor of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase. Erlotinib is developed by OSI Pharmaceuticals, Genentech and Roche, and marketed by Astellas Pharm Global Development under the trade name TARCEVA.

### - FDA Approval Summary of Erlotinib (TARCEVA)

RELAY NCT02411448	Non-small cell lung carcinoma (Approved on 2020/05/29)
	EGFR ex19del or L858R
	Erlotinib + ramucirumab vs. Erlotinib + placebo [PFS(M): 19.4 vs. 12.4]
EURTAC <sup>[63]</sup> NCT00446225	Non-small cell lung carcinoma (Approved on 2013/05/14)
	EGFR ex19del or L858R
	Erlotinib vs. Cisplatin + gemcitabine or cisplatin + docetaxel or carboplatin + gemcitabine or carboplatin + docetaxel [PFS(M): 10.4 vs. 5.2]
PA.3 <sup>[64]</sup> NCT00026338	Pancreatic cancer (Approved on 2005/11/02)
	-
	Gemcitabine vs. Placebo [OS(M): 6.4 vs. 6]

## Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

### - FDA Approval Summary of Everolimus (AFINITOR)

RADIANT-4 <sup>[65]</sup> NCT01524783	Lung or gastrointestinal neuroendocrine tumor (Approved on 2016/02/26)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
BOLERO-2 <sup>[66]</sup> NCT00863655	Breast cancer (Approved on 2012/07/20)
	ER+/HER2-
	Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
EXIST-2 NCT00790400	Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma (Approved on 2012/04/26)
	-
	Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
RADIANT-3 <sup>[67]</sup> NCT00510068	Pancreatic neuroendocrine tumor (Approved on 2011/05/05)
	-
	Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
EXIST-1 <sup>[68]</sup> NCT00789828	Subependymal giant cell astrocytoma (Approved on 2010/10/29)
	-
	Everolimus vs. Placebo [ORR(%): 35.0]
RECORD-1 <sup>[69]</sup> NCT00410124	Renal cell carcinoma (Approved on 2009/05/30)
	-
	Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

# ACT Onco<sup>®</sup> + Report

## Gefitinib (IRESSA)

Gefitinib is a small molecule inhibitor of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase. Gefitinib is developed and marketed by AstraZeneca under the trade name IRESSA.

### - FDA Approval Summary of Gefitinib (IRESSA)

IFUM <sup>[70]</sup> NCT01203917	Non-small cell lung carcinoma (Approved on 2015/07/13)
	EGFR ex19del or L858R
	Gefitinib [ORR(%): 50.0]

## Niraparib (Zejula)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name Zejula.

### - FDA Approval Summary of Niraparib (Zejula)

PRIMA NCT02655016	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2020/04/29)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
NOVA <sup>[71]</sup> NCT01847274	Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma (Approved on 2017/03/27)
	-
	Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

## Olaparib (Lynparza)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name Lynparza.

### - FDA Approval Summary of Olaparib (Lynparza)

PROpel NCT03732820	Prostate cancer (Approved on 2023/05/31)
	BRCA mutation
	Olaparib + abiraterone + prednisone vs. Placebo + abiraterone + prednisone [rPFS(M): not reached vs. 8]
OlympiA NCT02032823	HER2-negative high-risk early breast cancer (Approved on 2022/03/11)
	HER2-/gBRCA mutation
	Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M): ]
PROfound <sup>[72]</sup> NCT02987543	Prostate cancer (Approved on 2020/05/19)
	HRR genes mutation
	Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
PAOLA-1 <sup>[73]</sup> NCT02477644	Ovarian cancer (Approved on 2020/05/08)
	HRD+
	Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
POLO <sup>[74]</sup> NCT02184195	Pancreatic adenocarcinoma (Approved on 2019/12/27)
	gBRCA mutation
	Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]

# ACT Onco<sup>®</sup> + Report

<b>SOLO-1</b> <sup>[75]</sup> NCT01844986	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/12/19)
	<b>gBRCA mutation or sBRCA mutation</b>
	Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
<b>OlympiAD</b> <sup>[76]</sup> NCT02000622	<b>Breast cancer</b> (Approved on 2018/02/06)
	<b>HER2-/gBRCA mutation</b>
	Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
<b>SOLO-2/ENGOT-Ov21</b> <sup>[77]</sup> NCT01874353	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	<b>gBRCA mutation</b>
	Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
<b>Study19</b> <sup>[78]</sup> NCT00753545	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	-
	Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]

## Osimertinib (TAGRISSO)

Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) for patients with tumors harboring EGFR T790M mutation. Osimertinib is developed and marketed by AstraZeneca under the trade name TAGRISSO.

### - FDA Approval Summary of Osimertinib (TAGRISSO)

<b>ADAURA</b> NCT02511106	<b>Non-small cell lung carcinoma</b> (Approved on 2020/12/18)
	<b>EGFR ex19del or L858R</b>
	Osimertinib vs. Placebo + adjuvant chemotherapy [DFS(M): NR vs. 19.6]
<b>FLAURA</b> <sup>[10]</sup> NCT02296125	<b>Non-small cell lung carcinoma</b> (Approved on 2018/04/18)
	<b>EGFR ex19del or L858R</b>
	Osimertinib vs. Gefitinib or erlotinib [PFS(M): 18.9 vs. 10.2]
<b>AURA3</b> <sup>[79]</sup> NCT02151981	<b>Non-small cell lung carcinoma</b> (Approved on 2017/03/30)
	<b>EGFR T790M</b>
	Osimertinib vs. Chemotherapy [PFS(M): 10.1 vs. 4.4]
<b>AURA</b> <sup>[80]</sup> NCT01802632	<b>Non-small cell lung carcinoma</b> (Approved on 2015/11/13)
	<b>EGFR T790M</b>
	Osimertinib [ORR(%): 59.0]

## Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

### - FDA Approval Summary of Rucaparib (RUBRACA)

<b>TRITON2</b> NCT02952534	<b>Prostate cancer</b> (Approved on 2020/05/15)
	<b>gBRCA mutation or sBRCA mutation</b>
	Rucaparib [ORR(%): 44.0, DOR(M): NE]
<b>ARIEL3</b> <sup>[81]</sup> NCT01968213	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/04/06)
	-
	Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]

# ACT Onco<sup>®</sup> + Report

## Selumetinib (KOSELUGO)

Selumetinib is a kinase inhibitor. Selumetinib is developed and marketed by AstraZeneca under the trade name KOSELUGO.

### - FDA Approval Summary of Selumetinib (KOSELUGO)

SPRINT NCT01362803	Plexiform neurofibromas (Approved on 2020/04/10)
	-
	Selumetinib [ORR(%): 66.0]

## Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

### - FDA Approval Summary of Talazoparib (TALZENNA)

TALAPRO-2 NCT03395197	Prostate cancer (Approved on 2023/06/20)
	HRR genes mutation
	Talazoparib + enzalutamide vs. Placebo + enzalutamide [rPFS(M): Not reached vs. 13.8]
EMBRACA <sup>[82]</sup> NCT01945775	Breast cancer (Approved on 2018/10/16)
	HER2-/gBRCA mutation
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

## Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

### - FDA Approval Summary of Temsirolimus (TORISEL)

[83] NCT00065468	Renal cell carcinoma (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn- $\alpha$ [OS(M): 10.9 vs. 7.3]

# ACT Onco® + Report

## Trametinib (MEKINIST)

Trametinib is an anti-cancer inhibitor which targets MEK1 and MEK2. Trametinib is developed and marketed by GlaxoSmithKline (GSK) under the trade name MEKINIST.

### - FDA Approval Summary of Trametinib (MEKINIST)

CDRB436G2201 NCT02684058	<b>Low -grade glioma</b> (Approved on 2023/03/09)
	<b>BRAF V600E</b>
	Dabrafenib + trametinib vs. Carboplatin + vincristine [ORR(%): 46.6 vs. 10.8]
BRF117019, NCI-MATCH, CTMT212X2101 NCT02034110, NCT02465060, NCT02124772	<b>Cancer</b> (Approved on 2022/06/22)
	<b>BRAF V600E</b>
	Dabrafenib + trametinib [ORR(adult patients)(%): 41.0, ORR(pediatric patients)(%): 25.0]
BRF117019 <sup>[84]</sup> NCT02034110	<b>Anaplastic thyroid cancer</b> (Approved on 2018/05/04)
	<b>BRAF V600E</b>
	Dabrafenib + trametinib [ORR(%): 61.0]
BRF113928 <sup>[85]</sup> NCT01336634	<b>Non-small cell lung cancer</b> (Approved on 2017/06/22)
	<b>BRAF V600E</b>
	Trametinib + dabrafenib vs. Dabrafenib [ORR(%): 63.0 vs. 27.0, DOR(M): 12.6 vs. 9.9]
COMBI-d <sup>[86]</sup> NCT01584648	<b>Melanoma</b> (Approved on 2014/01/10)
	<b>BRAF V600E/K</b>
	Trametinib + dabrafenib vs. Dabrafenib + placebo [PFS(M): 9.3 vs. 8.8]
METRIC <sup>[87]</sup> NCT01245062	<b>Melanoma</b> (Approved on 2013/05/29)
	<b>BRAF V600E/K</b>
	Trametinib vs. Dacarbazine or paclitaxel [PFS(M): 4.8 vs. 1.5]

D=day; W=week; M=month

# ACT Onco<sup>®</sup> + Report

## ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.



# ACT Onco<sup>®</sup> + Report


## SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
EGFR	L858R	21	c.2573T>G	NM_005228	COSM6224	28.0%	2466
TP53	T155N	5	c.464C>A	NM_000546	COSM11218	25.7%	634

### - Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



# ACT Onco<sup>®</sup> + Report

## OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
CARD11	A687V	16	c.2060C>T	NM_032415	-	49.7%	354
ERCC5	G1080Q	15	c.3238_3239delinsCA	NM_000123	-	59.3%	199
ERCC5	P524L	8	c.1571C>T	NM_000123	-	39.9%	1049
FGFR3	V329I	8	c.985G>A	NM_000142	COSM6928248	64.2%	148
GNAQ	D130N	3	c.388G>A	NM_002072	-	62.3%	1072
KAT6A	R469L	8	c.1406G>T	NM_006766	-	53.0%	722
KMT2C	R380L	8	c.1139G>T	NM_170606	COSM225885	5.4%	3997
LRP1B	R3069H	58	c.9206G>A	NM_018557	COSM266850	41.5%	458
RET	R600W	10	c.1798C>T	NM_020975	COSM3786677	60.3%	209
RPTOR	V1147I	29	c.3439G>A	NM_020761	COSM6769672	45.5%	694


### Note:

- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.

# ACT Onco<sup>®</sup> + Report

## TEST DETAILS

### SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Mar 16, 2023
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11211680A
- Collection site: Lung
- Examined by: Dr. Yun-An Chen
  1. The percentage of viable tumor cells in total cells in the whole slide (%): 20%
  2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 40%
  3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
  4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
  5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

## RUN QC

- Panel: ACTOnco<sup>®</sup>+

### DNA test

- Mean Depth: 936x
- Target Base Coverage at 100x: 95%

### RNA test

- Average unique RNA Start Sites per control GSP2: 79

## LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

# ACTOnco<sup>®</sup> + Report

## NEXT-GENERATION SEQUENCING (NGS) METHODS

### DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage  $\geq 20$ , allele frequency  $\geq 5\%$  and actionable variants with allele frequency  $\geq 2\%$  were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at  $100\times \geq 85\%$  with a mean coverage  $\geq 500\times$ .

Variants reported in Genome Aggregation database with  $> 1\%$  minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation  $\geq 0.3$  were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco<sup>®</sup> + to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to  $\geq 7.5$  mutations per megabase (Muts/Mb); TMB-Low corresponds to  $< 7.5$  Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is  $< 30\%$ .

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in  $> 400$  genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

### RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be  $\geq 10$ .

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2  $\geq 3$ ; (2) Number of supporting reads spanning the fusion junction  $\geq 5$ ; (3) Percentage of supporting reads spanning the fusion junction  $\geq 10\%$ ; (4) Fusions annotated in Quiver Gene Fusion Database.

# ACT Onco<sup>®</sup> + Report

## DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

## Variant Analysis:

解剖病理專科醫師朱盈霞  
Ying-Hsia Chu, M.D.  
病解字第 000653 號



## Sign Off

解剖病理專科醫師朱盈霞  
Ying-Hsia Chu, M.D.  
病解字第 000653 號



# ACT Onco<sup>®</sup> + Report

## GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTS11	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BAR1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMP1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTX	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOX2*	FOX1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBK	IKBE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDMSA	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MAIT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC1B1*
SLC1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFB2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

\*Analysis of copy number alterations NOT available.

## FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------




# ACT Onco<sup>®</sup> + Report

## APPENDIX

### POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION

Gene	Therapies	Possible effect
<i>NF1</i>	Binimetinib, Cobimetinib, Everolimus, Selumetinib, Temsirolimus, Trametinib	<b>sensitive</b>
<i>BRCA2</i>	Niraparib, Olaparib, Rucaparib, Talazoparib	<b>sensitive</b>
<i>NF1</i>	Afatinib, Cabozantinib, Cetuximab, Crizotinib, Erlotinib, Gefitinib, Lapatinib, Trastuzumab, Vemurafenib	<b>resistant</b>


### SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



1: Olaparib, Niraparib, Rucaparib, Talazoparib

# ACT Onco<sup>®</sup> + Report


## Receptor Tyrosine Kinase/Growth Factor Signalling



1: Gefitinib, Afatinib, Erlotinib, Osimertinib, Dacomitinib; 2: Afatinib

## PI3K/AKT Signalling

## Ras/Raf/MEK Signalling



1: Everolimus, Temsirolimus; 2: Trametinib, Selumetinib, Binimetinib, Cobimetinib

# ACT Onco<sup>®</sup> + Report

## DISCLAIMER

### 法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

### 醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

### 基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

### 證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

### 責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

# ACT Onco<sup>®</sup> + Report

## REFERENCE

1. PMID: 18045542; 2007, Cell;131(5):1018  
SnapShot: EGFR signaling pathway.
2. PMID: 10880430; 2000, EMBO J;19(13):3159-67  
The ErbB signaling network: receptor heterodimerization in development and cancer.
3. PMID: 15329413; 2004, Proc Natl Acad Sci U S A; 101(36):13306-11  
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
4. PMID: 11426640; 2000, Oncogene;19(56):6550-65  
The EGF receptor family as targets for cancer therapy.
5. PMID: 17318210; 2007, Nat Rev Cancer;7(3):169-81  
Epidermal growth factor receptor mutations in lung cancer.
6. PMID: 22263017; 2010, J Thorac Dis;2(1):48-51  
Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
7. PMID: 28351930; 2017, Clin Cancer Res;23(15):4242-4250  
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
8. PMID: 28958502; 2017, Lancet Oncol;18(11):1454-1466  
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
9. PMID: 29653820; 2018, Clin Lung Cancer;19(4):e465-e479  
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
10. PMID: 29151359; 2018, N Engl J Med;378(2):113-125  
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
11. PMID: 24739573; 2014, Nat Rev Cancer;14(5):359-70  
Unravelling mechanisms of p53-mediated tumour suppression.
12. PMID: 21125671; 2011, J Pathol;223(2):137-46  
Haplo-insufficiency: a driving force in cancer.
13. PMID: 27998224; 2016, J Clin Oncol;34(36):4354-4361  
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
14. PMID: 26646755; 2016, Ann Oncol;27(3):539-43  
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
15. PMID: 25669829; 2015, Ann Oncol;26(5):1012-1018  
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
16. PMID: 27466356; 2016, Mol Cancer Ther;15(10):2475-2485  
TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
17. PMID: 23670029; 2013, Oncotarget;4(5):705-14  
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.

# ACT Onco<sup>®</sup> + Report

18. PMID: 17145525; 2006, Semin Oncol;33(5 Suppl 10):S8-14  
Bevacizumab in combination with chemotherapy : first-line treatment of patients with metastatic colorectal cancer.
19. PMID: 21399868; 2011, Int J Oncol;38(5):1445-52  
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
20. PMID: 20549698; 2011, Int J Cancer;128(8):1813-21  
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
21. PMID: 10786679; 2000, Cancer Res;60(8):2155-62  
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
22. PMID: 25672981; 2015, Cancer Res;75(7):1187-90  
VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.
23. PMID: 11239455; 2001, Mol Cell;7(2):263-72  
BRCA2 is required for homology-directed repair of chromosomal breaks.
24. PMID: 17597348; 2007, Ann Surg Oncol;14(9):2510-8  
Heterogeneous loss of the wild-type BRCA allele in human breast tumorigenesis.
25. PMID: 22193408; 2011, Nat Rev Cancer;12(1):68-78  
BRCA1 and BRCA2: different roles in a common pathway of genome protection.
26. PMID: 27283171; 2016, J Natl Compr Canc Netw;14(6):795-806  
The Relevance of Hereditary Cancer Risks to Precision Oncology: What Should Providers Consider When Conducting Tumor Genomic Profiling?
27. PMID: 8563751; 1996, Nat Genet;12(2):144-8  
Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
28. PMID: 1946382; 1991, Proc Natl Acad Sci U S A;88(21):9658-62  
Identification of the neurofibromatosis type 1 gene product.
29. PMID: 2116237; 1990, Cell;62(3):599-608  
The neurofibromatosis type 1 gene encodes a protein related to GAP.
30. PMID: 2121370; 1990, Cell;63(4):843-9  
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21.
31. PMID: 14502561; 2003, J Cell Physiol;197(2):214-24  
NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity.
32. PMID: 19479903; 2009, Mol Carcinog;48(11):1005-17  
Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase.
33. PMID: 28680740; 2017, Adv Med Biol;118():83-122  
Haploinsufficient tumor suppressor genes.
34. PMID: 10442636; 1999, Oncogene;18(31):4450-9  
Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation.
35. PMID: 16288202; 2006, Oncogene;25(16):2297-303  
Nf1 haploinsufficiency augments angiogenesis.
36. PMID: 18089636; 2008, Hum Mol Genet;17(7):936-48  
Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.
37. PMID: 7920653; 1994, Nat Genet;7(3):353-61  
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

# ACT Onco<sup>®</sup> + Report

38. PMID: 25026295; 2014, Oncotarget;5(15):5873-92  
The NF1 gene revisited - from bench to bedside.
39. PMID: 29892687; 2018, Gynecol Oncol Rep;23():41-44  
Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1.
40. PMID: 29926297; 2018, Breast Cancer Res Treat;171(3):719-735  
Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
41. PMID: 28637487; 2017, Hum Genomics;11(1):13  
The NF1 somatic mutational landscape in sporadic human cancers.
42. PMID: 15840687; 2005, Gut;54(8):1129-35  
NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer.
43. PMID: 20129251; 2010, Cancer Cell;17(1):98-110  
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
44. PMID: 27158780; 2016, Nat Genet;48(6):607-16  
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
45. PMID: 32669708; 2020, Nature;583(7818):807-812  
The National Lung Matrix Trial of personalized therapy in lung cancer.
46. PMID: 21482774; 2012, Proc Natl Acad Sci U S A;109(8):2730-5  
Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.
47. PMID: 24535670; 2014, Cancer Discov;4(5):606-19  
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
48. PMID: 29703253; 2018, BMC Cancer;18(1):479  
SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
49. PMID: 30858928; 2019, Oncotarget;10(14):1440-1457  
CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition.
50. PMID: 24576830; 2014, Cancer Res;74(8):2340-50  
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
51. PMID: 23288408; 2013, Cancer Discov;3(3):350-62  
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
52. PMID: 24265153; 2014, Cancer Discov;4(1):94-109  
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
53. PMID: 30269082; 2019, Gut;68(7):1152-1161  
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
54. PMID: 26936308; 2016, J Clin Pharm Ther;41(3):357-359  
Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.
55. PMID: 26859683; 2016, Oncotarget;7(9):10547-56  
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
56. PMID: 32122926; 2020, Clin Cancer Res;26(12):2932-2945  
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1



# ACT Onco<sup>®</sup> + Report

## Fusions.

57. PMID: 22573716; 2012, Cancer Res;72(13):3350-9  
Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
58. PMID: 23209032; 2013, Clin Cancer Res;19(2):450-61  
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
59. PMID: 26156651; 2015, Lancet Oncol;16(8):897-907  
Afinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
60. PMID: 23816960; 2013, J Clin Oncol;31(27):3327-34  
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
61. PMID: 29573941; 2018, Lancet Oncol;19(5):603-615  
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
62. PMID: 27480103; 2016, Lancet Oncol;17(9):1248-60  
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
63. PMID: 22285168; 2012, Lancet Oncol;13(3):239-46  
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EORTC): a multicentre, open-label, randomised phase 3 trial.
64. PMID: 17452677; 2007, J Clin Oncol;25(15):1960-6  
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
65. PMID: 26703889; 2016, Lancet;387(10022):968-977  
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
66. PMID: 22149876; 2012, N Engl J Med;366(6):520-9  
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
67. PMID: 21306238; 2011, N Engl J Med;364(6):514-23  
Everolimus for advanced pancreatic neuroendocrine tumors.
68. PMID: 23158522; 2013, Lancet;381(9861):125-32  
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
69. PMID: 18653228; 2008, Lancet;372(9637):449-56  
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
70. PMID: 24263064; 2014, Br J Cancer;110(1):55-62  
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
71. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164  
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
72. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102  
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
73. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428  
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

# ACT Onco<sup>®</sup> + Report

74. PMID: 31157963; 2019, N Engl J Med;381(4):317-327  
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
75. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505  
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
76. PMID: 28578601; 2017, N Engl J Med;377(6):523-533  
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
77. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284  
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
78. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589  
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
79. PMID: 27959700; 2017, N Engl J Med;376(7):629-640  
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
80. PMID: 25923549; 2015, N Engl J Med;372(18):1689-99  
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
81. PMID: 28916367; 2017, Lancet;390(10106):1949-1961  
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
82. PMID: 30110579; 2018, N Engl J Med;379(8):753-763  
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
83. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81  
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
84. PMID: 29072975; 2018, J Clin Oncol;36(1):7-13  
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
85. PMID: 27080216; 2016, Lancet Oncol;17(5):642-50  
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
86. PMID: 25265492; 2014, N Engl J Med;371(20):1877-88  
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
87. PMID: 22663011; 2012, N Engl J Med;367(2):107-14  
Improved survival with MEK inhibition in BRAF-mutated melanoma.